Dionysia Kefala, PhD candidate at the ICT, participated in the 2nd Translational Research Conference: Immune & Cellular Therapies: Focus on Advanced Gene-Engineered Immune Cells in Berlin, Germany organized by the European School of Hematology on September 12-14, 2022.
Dionysia Kefala presented the study on “Pre-clinical development of a decitabine-induced regulatory HLAG+CD4+ T cell-enriched cell product (iG-Treg) against Graft-vs-Host-Disease” which was accepted as a brief oral presentation . She discussed the preclinical development and characterization of a novel cell product (iG-Tregs) against graft-versus-host disease, a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation. This cell product is soon to be evaluated in a phase I/II clinical study (EUDRACT 2021-006367-26).
Finally, studies by distinguished researchers in the field of cell and gene therapies were presented at the conference, giving rise to new research ideas.